Authors


John Nelson, Brand Insights Contributor, Head of Strategy, CultHealth

Latest:

Text ROI to 55150

Channel mix nirvana. It’s like a group of superheroes with all different strengths; working together to achieve the extraordinary. Deploy different channels to achieve different objectives.


Myra Reinhardt, Brand Insights Contributor, VP of Product Innovation and Analytics, Lash Group

Latest:

Evaluating Electronic Benefit Verification Solutions for Your Patient Support Program

As specialty therapies evolve and more treatment options for chronic and complex diseases become available, patients are seeking treatment options that are both effective and affordable.


Vinay Torani

Latest:

505(b)(2): A Pathway to Competitiveness Through Innovation for Specialty and Generic Companies

As the market for specialty and generic products continues to become more competitive and pricing pressures increase, the 505(b)(2) pathway may allow companies more options to diversify their portfolios.


Eduardo Schur

Latest:

Commercial Models for the Changing Life Sciences Market

Life sciences companies have an opportunity to craft a sales approach that resonates with clients, protects against future disruptions and stands out from the competition.


Mohit Jain

Latest:

505(b)(2): A Pathway to Competitiveness Through Innovation for Specialty and Generic Companies

As the market for specialty and generic products continues to become more competitive and pricing pressures increase, the 505(b)(2) pathway may allow companies more options to diversify their portfolios.


Doug Balogh

Latest:

505(b)(2): A Pathway to Competitiveness Through Innovation for Specialty and Generic Companies

As the market for specialty and generic products continues to become more competitive and pricing pressures increase, the 505(b)(2) pathway may allow companies more options to diversify their portfolios.


Wolfgang Bauriedel

Latest:

Beyond “Tech Talent”: New Leadership in Pharma’s Digital Age

With an increase in digital technology being utilized as a strategic differentiator and business enabler in pharma, where is talent coming from?


Maneesh Dube

Latest:

Beyond “Tech Talent”: New Leadership in Pharma’s Digital Age

With an increase in digital technology being utilized as a strategic differentiator and business enabler in pharma, where is talent coming from?


Sandy Jennings

Latest:

A Bad Deal with Data?

Approach for pharma field sales reps in need of reboot.


Melanie Sena

Latest:

435 New Medicines in Development for “Older Americans”

According to a new report by the Pharmaceutical Research and Manufacturers of America (PhRMA), America’s biopharmaceutical research companies are developing 435 new medicines to target 15 leading chronic conditions affecting the Medicare population.




Guenter Kloucek

Latest:

Turning Commercial Compliance Roadblocks into a Springboard for Innovation

While new regulatory requirements are often seen as a roadblock, they also present an opportunity to develop new and innovative solutions.


Friedemann Lutz

Latest:

Turning Commercial Compliance Roadblocks into a Springboard for Innovation

While new regulatory requirements are often seen as a roadblock, they also present an opportunity to develop new and innovative solutions.


Terry G. Mahn

Latest:

The Bad Rap on Pharma: In Defense of Patents

A look at drug pricing and patents and the role for patents and how they are under attack.


Thomas Bertels

Latest:

Turning Commercial Compliance Roadblocks into a Springboard for Innovation

While new regulatory requirements are often seen as a roadblock, they also present an opportunity to develop new and innovative solutions.


Ted Prusik

Latest:

Cure for the Common Cold Chain Break

In medicines, as in life, the journey is just as important as the end result


Stephanie Brewer, PhD

Latest:

How to Communicate About an Ongoing Epidemic of Historic Proportions

The industry faces a problem of medical education and communication in regards to vaccinations.


Barbara Blasso

Latest:

How to Communicate About an Ongoing Epidemic of Historic Proportions

The industry faces a problem of medical education and communication in regards to vaccinations.


Laura Wilson, Brand Insights Contributor, Patient Strategy, Fingerpaint

Latest:

How Rare Disease Marketing Will Stretch Beyond the Patient

The foundation of a strong rare disease marketing program must be built on the comprehensive knowledge of how the life-altering disease impacts all areas of a patient’s life.


Jonathan Romeo, Brand Insights Contributor, Brand Strategy, Fingerpaint

Latest:

How Rare Disease Marketing Will Stretch Beyond the Patient

The foundation of a strong rare disease marketing program must be built on the comprehensive knowledge of how the life-altering disease impacts all areas of a patient’s life.




Shannon L. Wiley

Latest:

California Law Requires Legal, Compliance Scrutiny to Maintain Pharma Data Sharing

A summary of the key impacts new law, California Consumer Privacy Act (CCPA), will have on business practices related to data flow in specialty pharma, and more.


Katie Rapp

Latest:

How Cell and Gene Therapy Companies Can Adapt in an Evolving Commercial Landscape

Three changes manufacturers should consider in the wake of COVID-19.


Jaime L. Barwig

Latest:

California Law Requires Legal, Compliance Scrutiny to Maintain Pharma Data Sharing

A summary of the key impacts new law, California Consumer Privacy Act (CCPA), will have on business practices related to data flow in specialty pharma, and more.


Mark Bouch

Latest:

Pharma Outsourcing: Keys to Productivity in 2020s

Eight lessons to drive better outsourcing decisions.


Dave Nellesen

Latest:

AMCP’s Updated Format V 4.1 has Implications for Manufacturers and Payers

AMCP Format Version 4.1 provides manufacturers with additional guidance to communicate evidence about potential new products or new uses to payers in a compliant fashion.


Sergio Ricardo Segovia Barbosa

Latest:

Tapping Brazil's Potential

Sergio Ricardo Segovia Barbosa looks at Brazil’s growing competitiveness in the biopharma sector.